Document
type: Class

Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis
related by: authorship 8686
type: Article
type: Document
page end: 380
related by: authorship 8683
accesstype: All Open Access, Green
issue: 2
most specific type: Document
volume: 141
doi: 10.1111/j.1365-2249.2005.02859.x
related by: authorship 8688
crisid: 1430
tradenames: humira
related by: authorship 8685
type: Thing
most specific type: Article
related by: authorship 8682
page start: 372
estado: published
has publication venue: Clinical and Experimental Immunology
origen: scopus
date time value: article date 1430
type: Generically Dependent Continuant
related by: authorship 8684
related by: authorship 8687
abstract: The aim of this study was to assess the effect of Adalimumab on different immune parameters in patients with RA. Adalimumab was administered (40 mg every other week for 26 weeks) to eight patients with RA that were refractory to conventional drug therapy. Peripheral blood samples were obtained at days 0, 15 and 180 of Adalimumab therapy, and the following immune parameters were assessed: Number, phenotype, and function of regulatory T lymphocytes. The induction of apoptosis of immune cells and the in vitro and in vivo reactivity towards M. tuberculosis were also analysed. All patients responded to Adalimumab (ACR response 50-70), and a modest but significant increase in the number and function of regulatory T cells was observed at day 15 of anti-TNF-α therapy. In addition, an increased percent of apoptotic cells was detected in the peripheral blood at day 15 of Adalimumab therapy. Unexpectedly, most of these effects were not further observed at day 180. However, two patients showed a persistent and marked reduction in the reactivity to M. tuberculosis. Although we have found that Adalimumab affects the number and function of regulatory T lymphocytes, and the apoptosis of immune cells, these effects are transient and its possible causal relationship with the therapeutic activity of this biological agent remains to be determined. Nevertheless, the down-regulatory effect of Adalimumab on the reactivity to M. tuberculosis could be related to an enhanced risk of tuberculosis reactivation. © 2005 British Society for Immunology.
chemicalscas: adalimumab, 331731-18-1; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; prednisone, 53-03-2; salazosulfapyridine, 599-79-1; adalimumab; Antibodies, Monoclonal; Antigens, Bacterial; Antirheumatic Agents; Tumor Necrosis Factor-alpha
type: Entity
pmid: 15996202
related by: authorship 8681
freetext keyword: Anti-TNF-α; Apoptosis; Humira; Mycobacteria; Regulatory T cells adalimumab; CD4 antigen; cytokine; cytotoxic T lymphocyte antigen 4; interleukin 10; interleukin 2 receptor alpha; methotrexate; monoclonal antibody; prednisone; salazosulfapyridine; transforming growth factor beta; tumor necrosis factor alpha; tumor necrosis factor alpha antibody; adult; apoptosis; arthritis; article; clinical article; controlled study; cytokine production; female; human; human cell; immunoreactivity; lymphocyte proliferation; male; Mycobacterium tuberculosis; priority journal; rheumatoid arthritis; T lymphocyte; treatment outcome; Adult; Antibodies, Monoclonal; Antigens, Bacterial; Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Cells, Cultured; Female; Humans; Immune Tolerance; Lymphocyte Count; Middle Aged; Mycobacterium tuberculosis; Pilot Projects; T-Lymphocyte Subsets; Tuberculin Test; Tumor Necrosis Factor-alpha
type: Continuant
type: Information Content Entity
e iscopus: 2-s2.0-22344439240
related by: authorship 8689

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

RDF description of Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis - http://orbis.uaslp.mx/vivo/individual/scopus1429
rights: termsOfUse
date: 2026-08-24T21:50:58
publisher: vivo
type: Document

Article
type: Class

Information Content Entity
type: Class

Clinical and Experimental Immunology
type: Journal
type: Collection
type: Thing
type: Information Content Entity
type: Generically Dependent Continuant
type: Entity
publication venue for: Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis
type: Periodical
type: Continuant
type: Document